– USA, CA – Revelation Biosciences Inc., a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced the appointment of Dr. Curt LaBelle, M.D. to its Board of Directors.
“We extend our warmest welcome to Dr. LaBelle and are delighted to add another talented leader to our Board,” said CEO, James Rolke. “His extensive knowledge of the biotech industry and his expertise will be highly valuable to the Company as we continue to execute on our goals of bringing REVTx-99 and REVDx-501 to patients.”
About Dr. Curt LaBelle
Dr. LaBelle has been investing in and working with life science companies for over 20 years. Since 2015, he has been President of the Global Health Investment Fund. GHIF is a pioneering impact fund with a proven record of generating attractive financial returns and tangible impact. The fund works to facilitate access to therapeutics and diagnostics among low-income populations. Dr. LaBelle also works with the AXA Prime Impact Fund and serves as a Board member for Alydia Health, Atomo Diagnostics (ASX: AT1), Atticus Medical, Eyenovia (Nasdaq: EYEN), and Z Optics.
“I am very impressed with all that the Revelation team accomplished in 2020,” said Dr. LaBelle. “I look forward to using my expertise to help the company as it advances in development.”
Dr. LaBelle received his M.D. and M.B.A from Columbia University.
About Revelation Biosciences Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic‑based therapies for the prevention and treatment of disease. The Company has several product candidates in development. REVTx‑99, the lead therapeutic candidate, is an intranasal immunomodulator for the early treatment of SARS‑CoV‑2 infection. An expansion of REVTx‑99 therapeutic indications is planned, targeting early treatment and prevention of respiratory viral infection such as influenza A or B, parainfluenza, and respiratory syncytial virus. REVTx‑200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx‑200 is based on the same technology used in REVTx-99. In addition to the Company’s therapeutic pipeline, Revelation is also developing REVDx‑501, a rapid point of care diagnostic that can be used to detect any respiratory viral infection regardless of virus type without the need for specialized instrumentation.
For more information: https://www.revbiosciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
